

**Clinical trial results:**

**test - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)**

**Summary**

EudraCT number	2015-005431-41
Trial protocol	PL RO HR
Global end of trial date	

**Results information**

Result version number	v1
This version publication date	27 September 2020
First version publication date	27 September 2020

**Trial information****Trial identification**

Sponsor protocol code	BN40900
-----------------------	---------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02073279
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	Medical Communications, Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	12 October 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 October 2018
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of satralizumab monotherapy compared with placebo in participants with NMO and NMOSD. In addition, safety, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of satralizumab were evaluated.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 August 2014
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 4
Country: Number of subjects enrolled	Canada: 11
Country: Number of subjects enrolled	Georgia: 1
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Malaysia: 1
Country: Number of subjects enrolled	Poland: 8
Country: Number of subjects enrolled	Turkey: 1
Country: Number of subjects enrolled	Taiwan: 4
Country: Number of subjects enrolled	Ukraine: 10
Country: Number of subjects enrolled	United States: 47
Country: Number of subjects enrolled	Croatia: 1
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Romania: 1
Worldwide total number of subjects	95
EEA total number of subjects	15

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	94
From 65 to 84 years	1
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at 44 investigational sites across 13 countries. The Double-blind (DB) period lasted up to the clinical cut-off date (CCOD: 12 Oct 2018) when the study reached 1.5 years since the date of randomization of the last participant enrolled. The study is ongoing in the open-label extension (OLE) period.

### Pre-assignment

Screening details:

Participants with neuromyelitis optica (NMO) or NMO spectrum disorder (NMOSD) were randomized 2:1 to receive either satralizumab 120 mg or matching placebo.

### Period 1

Period 1 title	Double-blind Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo, then Satralizumab

Arm description:

Participants received matching placebo, subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks.

<b>Arm title</b>	Satralizumab, then Satralizumab
------------------	---------------------------------

Arm description:

Participants received satralizumab 120 mg subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Experimental
Investigational medicinal product name	Satralizumab
Investigational medicinal product code	
Other name	SA237
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

---

**Dosage and administration details:**

Satralizumab was administered SC at Weeks 0, 2, and 4, and thereafter once every 4 weeks.

<b>Number of subjects in period 1</b>	Placebo, then Satralizumab	Satralizumab, then Satralizumab
Started	32	63
Completed	17	16
Not completed	15	47
Consent withdrawn by subject	2	2
Adverse event, non-fatal	1	1
Ongoing in study	11	40
Reason Not Specified	1	2
Refused Treatment/Did Not Cooperate	-	1
Protocol deviation	-	1

---

**Period 2**

Period 2 title	Open-label Extension Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo, then Satralizumab

**Arm description:**

Participants received matching placebo, subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Placebo was administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4

weeks.

<b>Arm title</b>	Satralizumab, then Satralizumab
------------------	---------------------------------

Arm description:

Participants received satralizumab 120 mg subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Arm type	Experimental
Investigational medicinal product name	Satralizumab
Investigational medicinal product code	
Other name	SA237
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Satralizumab was administered SC at Weeks 0, 2, and 4, and thereafter once every 4 weeks.

<b>Number of subjects in period 2</b>	Placebo, then Satralizumab	Satralizumab, then Satralizumab
Started	17	16
Completed	0	0
Not completed	17	16
Consent withdrawn by subject	1	1
Ongoing in study	14	13
Reason Not Specified	1	1
Refused Treatment/Did Not Cooperate	-	1
Lack of efficacy	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo, then Satralizumab
-----------------------	----------------------------

Reporting group description:

Participants received matching placebo, subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Reporting group title	Satralizumab, then Satralizumab
-----------------------	---------------------------------

Reporting group description:

Participants received satralizumab 120 mg subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.

Reporting group values	Placebo, then Satralizumab	Satralizumab, then Satralizumab	Total
Number of subjects	32	63	95
Age categorical			
Units: Subjects			
Adults (18-64 years)	32	62	94
From 65-84 years	0	1	1
Age Continuous			
Units: Years			
arithmetic mean	40.5	45.3	
standard deviation	± 10.5	± 12.0	-
Sex: Female, Male			
Units: Participants			
Male	1	17	18
Female	31	46	77

## End points

### End points reporting groups

Reporting group title	Placebo, then Satralizumab
Reporting group description: Participants received matching placebo, subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.	
Reporting group title	Satralizumab, then Satralizumab
Reporting group description: Participants received satralizumab 120 mg subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.	
Reporting group title	Placebo, then Satralizumab
Reporting group description: Participants received matching placebo, subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to initiate satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.	
Reporting group title	Satralizumab, then Satralizumab
Reporting group description: Participants received satralizumab 120 mg subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD). At the CCOD, participants who had not experienced a relapse during the DB period were invited to continue satralizumab 120 mg SC injection (at Weeks 0, 2 and 4, and Q4W thereafter) after 4 weeks from their last study treatment dose in the DB period.	

### Primary: Time to First Protocol-Defined Relapse (TFR) in the Double-Blind (DB) Period

End point title	Time to First Protocol-Defined Relapse (TFR) in the Double-Blind (DB) Period
End point description: TFR is time from randomization to first occurrence of relapse in the DB period. Protocol-defined relapse was occurrence of new/worsening neurological symptoms attributable to NMO/NMOSD. Symptoms persisted for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New/worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (2 relapses with onset days in 30 days of one another was counted as 1 relapse), onset date used in analysis was the date of first relapse. Intent-to-treat (ITT) population: all randomized participants. 999999=upper limit of CI was not reached due to low number of participants with events. 99999=median was not reached due to low number of participants with events.	
End point type	Primary
End point timeframe: Up to Week 216	



End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: weeks				
median (confidence interval 95%)	128.3 (29.9 to 999999)	99999 (135.7 to 999999)		

## Statistical analyses

Statistical analysis title	Satralizumab versus Placebo
Statistical analysis description:	
Stratified by prior therapy (B-cell depleting therapy or immunosuppressants/others) and most recent attack (first attack or relapse).	
Comparison groups	Satralizumab, then Satralizumab v Placebo, then Satralizumab
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0184
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.23
upper limit	0.89

## Secondary: Change in Visual Analogue Scale (VAS) for Pain from Baseline to Week 24

End point title	Change in Visual Analogue Scale (VAS) for Pain from Baseline to Week 24
End point description:	
<p>The VAS is a subjective measure of pain consisting of a 100 mm line with two endpoints representing 0 = "no pain" and 100 = "pain as bad as it could be". Participants rated their pain by placing a mark on the line corresponding to their current level of pain. The distance along the line from the "no pain" marker was measured with a ruler giving a pain score out of 100. A higher score indicated more pain and lower scores reflected a better health state. A negative change from baseline indicates an improvement. ANCOVA was used for analysis to report the adjusted mean and standard error (SE). ITT population included all participants randomized to the treatment groups. Missing data were imputed by BOCF method.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard error)				
Baseline (n=32, 62)	27.563 ( $\pm$ 5.438)	31.661 ( $\pm$ 3.665)		
Change from Baseline to Week 24 (n=32, 62)	-5.949 ( $\pm$ 4.832)	-2.735 ( $\pm$ 4.260)		

### Statistical analyses

<b>Statistical analysis title</b>	Satralizumab versus Placebo
Comparison groups	Placebo, then Satralizumab v Satralizumab, then Satralizumab
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4436 <sup>[1]</sup>
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	3.215
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.086
upper limit	11.515
Variability estimate	Standard error of the mean
Dispersion value	4.178

Notes:

[1] - ANCOVA model: treatment group as fixed effect and baseline measurements, prior therapy, most recent attack (first attack/relapse) as covariates.

### Secondary: Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale from Baseline to Week 24

End point title	Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale from Baseline to Week 24
-----------------	---

End point description:

The FACIT Fatigue scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. As each of the 13 items of the scale ranges from 0-4, the range of possible scores was computed using FACIT scoring algorithm as 0-52, where 0 is the worst possible score and 52 the best which indicated less fatigue. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. Missing data were imputed by BOCF method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard error)				
Baseline (n=32, 62)	29.656 ( $\pm$ 2.280)	30.590 ( $\pm$ 1.492)		
Change from Baseline to Week 24 (n=32, 62)	3.602 ( $\pm$ 1.820)	5.709 ( $\pm$ 1.610)		

## Statistical analyses

Statistical analysis title	Satralizumab versus Placebo
Comparison groups	Placebo, then Satralizumab v Satralizumab, then Satralizumab
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1824 <sup>[2]</sup>
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	2.107
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.008
upper limit	5.221
Variability estimate	Standard error of the mean
Dispersion value	1.567

Notes:

[2] - ANCOVA model: treatment group as fixed effect and baseline measurements, prior therapy, most recent attack (first attack/relapse) as covariates.

## Secondary: Relapse-Free Rate During the DB Period

End point title	Relapse-Free Rate During the DB Period
End point description:	Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onset days that were 30 days of one another, they were counted only as 1 relapse), and onset date used in analysis was the date of first relapse. ITT population included all participants randomized to the treatment groups. 6666= 0 participants.
End point type	Secondary
End point timeframe:	
Up to Week 216	

<b>End point values</b>	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	23	56		
Units: percentage				
number (not applicable)				
Week 12 (n=23, 56)	74.87	88.89		
Week 24 (n=22, 54)	71.61	85.71		
Week 36 (n=19, 49)	61.85	79.37		
Week 48 (n=19, 46)	61.85	76.13		
Week 72 (n=13, 43)	51.21	74.40		
Week 96 (n=9, 30)	51.21	72.14		
Week 120 (n=3, 16)	51.21	72.14		
Week 144 (n=2, 12)	34.14	62.80		
Week 168 (n=1, 10)	34.14	62.80		
Week 192 (n=1, 3)	34.14	62.80		
Week 216 (n=1, 0)	34.14	6666		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Annualized Relapse Rate (ARR) During the DB Period

End point title	Annualized Relapse Rate (ARR) During the DB Period
-----------------	--

End point description:

The ARR is calculated as the total number participants with relapses experienced divided by the patient-years at risk. Protocol-defined relapse was occurrence of new/worsening neurological symptoms attributable to neurological NMO/NMOSD. Symptoms persisted for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New/worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (2 relapses with onset days in 30 days of one another was counted as 1 relapse), onset date used in analysis was the date of first relapse. ITT population included all participants randomized to the treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 216

<b>End point values</b>	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: patients w relapse/patient-years at risk				
number (confidence interval 95%)	0.41 (0.24 to	0.17 (0.10 to		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Short Form Generic Health Survey (SF-36) Bodily Pain Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Short Form Generic Health Survey (SF-36) Bodily Pain Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	42.86 ( $\pm$ 11.28)	43.20 ( $\pm$ 11.08)		
Change from Baseline at Week 24 (n=20, 54)	-0.89 ( $\pm$ 8.35)	-0.13 ( $\pm$ 8.09)		
Change from Baseline at Week 48 (n=18, 46)	1.75 ( $\pm$ 5.42)	1.36 ( $\pm$ 8.89)		
Change from Baseline at Week 72 (n=13, 43)	3.19 ( $\pm$ 8.04)	0.91 ( $\pm$ 9.23)		
Change from Baseline at Week 96 (n=8, 31)	3.43 ( $\pm$ 5.60)	2.38 ( $\pm$ 7.82)		
Change from Baseline at Week 120 (n=3, 16)	0.00 ( $\pm$ 8.07)	0.53 ( $\pm$ 6.21)		
Change from Baseline at Week 144 (n=2, 12)	-2.22 ( $\pm$ 8.84)	2.59 ( $\pm$ 6.66)		
Change from Baseline at Week 168 (n=1, 10)	0.80 ( $\pm$ 9999)	4.19 ( $\pm$ 7.01)		
Change from Baseline at Week 192 (n=1, 2)	-8.47 ( $\pm$ 9999)	0 ( $\pm$ 0)		
Change from Baseline at Week 216 (n=1, 0)	-12.50 ( $\pm$ 9999)	6666 ( $\pm$ 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants analyzed for the time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	39.43 (± 9.50)	39.72 (± 10.41)		
Change from Baseline at Week 24 (n=20, 54)	-0.52 (± 9.96)	0.49 (± 6.46)		
Change from Baseline at Week 48 (n=18, 46)	1.85 (± 9.72)	1.01 (± 7.61)		
Change from Baseline at Week 72 (n=13, 43)	4.83 (± 12.41)	3.21 (± 6.57)		
Change from Baseline at Week 96 (n=8, 31)	6.60 (± 9.10)	3.45 (± 6.42)		
Change from Baseline at Week 120 (n=3, 16)	8.72 (± 13.55)	3.60 (± 7.02)		
Change from Baseline at Week 144 (n=2, 12)	5.23 (± 14.11)	2.82 (± 8.00)		
Change from Baseline at Week 168 (n=1, 10)	-7.13 (± 9999)	5.04 (± 9.45)		
Change from Baseline at Week 192 (n=1, 2)	-4.75 (± 9999)	8.32 (± 11.77)		
Change from Baseline at Week 216 (n=1, 0)	-4.75 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	42.86 (± 12.69)	46.78 (± 10.10)		
Change from Baseline at Week 24 (n=20, 54)	0.79 (± 9.02)	1.84 (± 7.05)		
Change from Baseline at Week 48 (n=18, 46)	-0.58 (± 7.32)	2.67 (± 7.89)		
Change from Baseline at Week 72 (n=13, 43)	2.62 (± 6.32)	1.95 (± 7.85)		
Change from Baseline at Week 96 (n=8, 31)	-3.60 (± 6.08)	2.36 (± 7.38)		
Change from Baseline at Week 120 (n=3, 16)	-2.62 (± 6.92)	0.82 (± 10.32)		
Change from Baseline at Week 144 (n=2, 12)	1.31 (± 1.85)	2.83 (± 9.43)		
Change from Baseline at Week 168 (n=1, 10)	5.23 (± 9999)	2.62 (± 8.89)		
Change from Baseline at Week 192 (n=1, 2)	-13.08 (± 9999)	-3.93 (± 12.95)		
Change from Baseline at Week 216 (n=1, 0)	-2.62 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	38.70 (± 12.24)	39.48 (± 10.99)		
Change from Baseline at Week 24 (n=20, 54)	2.20 (± 4.62)	1.96 (± 6.12)		
Change from Baseline at Week 48 (n=18, 46)	2.34 (± 6.90)	3.33 (± 6.76)		
Change from Baseline at Week 72 (n=13, 43)	6.62 (± 9.71)	2.99 (± 6.94)		
Change from Baseline at Week 96 (n=8, 31)	5.50 (± 9.62)	3.59 (± 7.49)		
Change from Baseline at Week 120 (n=3, 16)	7.01 (± 8.63)	1.94 (± 8.05)		
Change from Baseline at Week 144 (n=2, 12)	4.79 (± 9.48)	3.19 (± 10.87)		
Change from Baseline at Week 168 (n=1, 10)	1.91 (± 9999)	-0.96 (± 8.62)		
Change from Baseline at Week 192 (n=1, 2)	-1.92 (± 9999)	4.78 (± 4.06)		
Change from Baseline at Week 216 (n=1, 0)	-3.83 (± 9999)	6666 (± 6666)		



## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	42.24 (± 13.09)	42.07 (± 13.62)		
Change from Baseline at Week 24 (n=20, 54)	-1.57 (± 15.67)	3.87 (± 11.27)		
Change from Baseline at Week 48 (n=18, 46)	0.78 (± 8.57)	2.73 (± 10.30)		
Change from Baseline at Week 72 (n=13, 43)	4.55 (± 7.96)	3.89 (± 9.22)		
Change from Baseline at Week 96 (n=8, 31)	3.05 (± 11.98)	1.12 (± 11.87)		
Change from Baseline at Week 120 (n=3, 16)	-12.77 (± 14.07)	1.31 (± 14.04)		
Change from Baseline at Week 144 (n=2, 12)	-12.19 (± 17.23)	1.74 (± 13.40)		
Change from Baseline at Week 168 (n=1, 10)	0.00 (± 9999)	-0.35 (± 11.89)		
Change from Baseline at Week 192 (n=1, 2)	-13.93 (± 9999)	-3.49 (± 4.93)		
Change from Baseline at Week 216 (n=1, 0)	-10.45 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	37.86 (± 11.28)	37.43 (± 11.55)		
Change from Baseline at Week 24 (n=20, 54)	3.14 (± 9.92)	3.52 (± 8.38)		
Change from Baseline at Week 48 (n=18, 46)	4.12 (± 7.24)	5.01 (± 8.25)		
Change from Baseline at Week 72 (n=13, 43)	5.70 (± 7.65)	4.59 (± 8.56)		
Change from Baseline at Week 96 (n=8, 31)	5.62 (± 6.35)	4.83 (± 8.31)		
Change from Baseline at Week 120 (n=3, 16)	2.25 (± 8.99)	3.18 (± 9.46)		
Change from Baseline at Week 144 (n=2, 12)	-3.37 (± 11.12)	2.43 (± 8.80)		
Change from Baseline at Week 168 (n=1, 10)	0.00 (± 9999)	0.00 (± 9.10)		
Change from Baseline at Week 192 (n=1, 2)	-6.74 (± 9999)	4.49 (± 6.35)		
Change from Baseline at Week 216 (n=1, 0)	-17.97 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	42.93 (± 13.22)	41.01 (± 11.66)		
Change from Baseline at Week 24 (n=20, 54)	1.76 (± 12.42)	2.42 (± 9.63)		
Change from Baseline at Week 48 (n=18, 46)	0.56 (± 10.59)	2.62 (± 8.17)		
Change from Baseline at Week 72 (n=13, 43)	0.39 (± 11.66)	3.96 (± 7.93)		
Change from Baseline at Week 96 (n=8, 31)	0.63 (± 1.77)	3.56 (± 7.89)		
Change from Baseline at Week 120 (n=3, 16)	-5.01 (± 13.26)	0.31 (± 8.48)		
Change from Baseline at Week 144 (n=2, 12)	7.52 (± 10.63)	3.76 (± 14.68)		
Change from Baseline at Week 168 (n=1, 10)	-5.01 (± 9999)	-1.50 (± 7.86)		
Change from Baseline at Week 192 (n=1, 2)	-5.01 (± 9999)	-2.51 (± 3.54)		
Change from Baseline at Week 216 (n=1, 0)	0.00 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period
End point description:	
<p>The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.</p>	
End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	40.72 (± 11.86)	46.02 (± 10.58)		
Change from Baseline at Week 24 (n=20, 54)	1.49 (± 10.22)	2.33 (± 8.29)		
Change from Baseline at Week 48 (n=18, 46)	4.79 (± 9.07)	4.15 (± 7.49)		
Change from Baseline at Week 72 (n=13, 43)	3.43 (± 9.38)	3.68 (± 6.43)		
Change from Baseline at Week 96 (n=8, 31)	0.00 (± 7.94)	4.34 (± 9.39)		
Change from Baseline at Week 120 (n=3, 16)	-1.98 (± 11.24)	3.96 (± 9.94)		
Change from Baseline at Week 144 (n=2, 12)	-9.41 (± 7.70)	4.95 (± 7.95)		
Change from Baseline at Week 168 (n=1, 10)	-5.94 (± 9999)	5.05 (± 6.58)		
Change from Baseline at Week 192 (n=1, 2)	-11.88 (± 9999)	0.00 (± 8.40)		
Change from Baseline at Week 216 (n=1, 0)	-11.88 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Mental Component Summary Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Mental Component Summary Scores at 24 Week Intervals During the DB Period
End point description:	
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.	
End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	44.03 (± 13.93)	46.43 (± 11.55)		
Change from Baseline at Week 24 (n=20, 54)	-0.28 (± 11.19)	2.89 (± 8.96)		
Change from Baseline at Week 48 (n=18, 46)	0.09 (± 8.96)	2.63 (± 8.04)		
Change from Baseline at Week 72 (n=13, 43)	1.54 (± 8.18)	3.17 (± 7.70)		
Change from Baseline at Week 96 (n=8, 31)	-2.65 (± 6.05)	1.91 (± 9.32)		
Change from Baseline at Week 120 (n=3, 16)	-10.65 (± 11.99)	1.03 (± 12.92)		
Change from Baseline at Week 144 (n=2, 12)	-5.40 (± 8.41)	2.98 (± 12.99)		
Change from Baseline at Week 168 (n=1, 10)	-0.61 (± 9999)	1.63 (± 11.86)		
Change from Baseline at Week 192 (n=1, 2)	-14.38 (± 9999)	-5.88 (± 7.54)		
Change from Baseline at Week 216 (n=1, 0)	-4.22 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	38.89 (± 11.20)	38.59 (± 9.68)		
Change from Baseline at Week 24 (n=20, 54)	1.78 (± 4.99)	1.05 (± 6.14)		
Change from Baseline at Week 48 (n=18, 46)	3.57 (± 4.94)	2.85 (± 4.90)		
Change from Baseline at Week 72 (n=13, 43)	5.68 (± 7.32)	2.87 (± 6.80)		
Change from Baseline at Week 96 (n=8, 31)	7.25 (± 7.08)	4.20 (± 5.90)		
Change from Baseline at Week 120 (n=3, 16)	8.95 (± 8.51)	2.68 (± 8.72)		
Change from Baseline at Week 144 (n=2, 12)	3.18 (± 10.67)	2.89 (± 7.11)		
Change from Baseline at Week 168 (n=1, 10)	-2.00 (± 9999)	1.83 (± 10.96)		
Change from Baseline at Week 192 (n=1, 2)	-1.79 (± 9999)	7.24 (± 3.35)		
Change from Baseline at Week 216 (n=1, 0)	-10.84 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The EQ-5D is a participant-answered questionnaire measuring 5 dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with 3 possible response categories: 1) no problems; 2) some problems; 3) severe problems. The scores from 5 dimensions are used as input to generate EQ-5D index score using scoring algorithm. The EQ-5D index score is scored on a scale of -0.2 to 1. A higher score reflects a better health state. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	0.7153 (± 0.2253)	0.6881 (± 0.2040)		
Change from Baseline at Week 24 (n=20, 53)	0.0031 (± 0.1602)	0.0188 (± 0.1812)		
Change from Baseline at Week 48 (n=18, 45)	0.0016 (± 0.1176)	0.0244 (± 0.1571)		
Change from Baseline at Week 72 (n=12, 42)	0.0582 (± 0.1498)	0.0238 (± 0.1323)		
Change from Baseline at Week 96 (n=8, 30)	0.0447 (± 0.1508)	0.0460 (± 0.1067)		
Change from Baseline at Week 120 (n=3, 16)	-0.0288 (± 0.1908)	0.0099 (± 0.1636)		
Change from Baseline at Week 144 (n=2, 12)	-0.1001 (± 0.1416)	0.0063 (± 0.2299)		
Change from Baseline at Week 168 (n=1, 10)	0.0000 (± 9999)	-0.0261 (± 0.2532)		
Change from Baseline at Week 192 (n=1, 2)	-0.2002 (± 9999)	0.0299 (± 0.0423)		
Change from Baseline at Week 216 (n=1, 0)	-0.2002 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Speed of Timed 25-Foot Walk (T25W) at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Speed of Timed 25-Foot Walk (T25W) at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The T25W is an assessment of walking ability. The time (in seconds) that the participant took to walk 25 feet was measured. Speed is calculated as 1/Timed 25-Foot Walk where time is measured in seconds. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	63		
Units: 1/seconds				
arithmetic mean (standard deviation)				
Baseline (n=29, 63)	0.1442 (± 0.0793)	0.1355 (± 0.0561)		
Change from Baseline at Week 24 (n=19, 53)	0.0030 (± 0.0374)	0.0040 (± 0.0225)		
Change from Baseline at Week 48 (n=16, 45)	0.0142 (± 0.0493)	0.0115 (± 0.0306)		
Change from Baseline at Week 72 (n=11, 43)	0.0205 (± 0.0531)	0.0071 (± 0.0257)		
Change from Baseline at Week 96 (n=6, 31)	-0.0031 (± 0.0251)	0.0081 (± 0.0253)		
Change from Baseline at Week 120 (n=3, 16)	0.0489 (± 0.0301)	0.0063 (± 0.0386)		
Change from Baseline at Week 144 (n=2, 12)	0.0388 (± 0.0572)	0.0003 (± 0.0443)		
Change from Baseline at Week 168 (n=1, 9)	-0.0656 (± 9999)	-0.0155 (± 0.0379)		
Change from Baseline at Week 192 (n=1, 2)	-0.0812 (± 9999)	-0.0304 (± 0.0360)		
Change from Baseline at Week 216 (n=1, 0)	-0.0917 (± 9999)	6666 (± 6666)		



## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Modified Rankin Scale (mRS) Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Modified Rankin Scale (mRS) Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The mRS is a 7-point disability scale that assesses the degree of disability in participants with neurological impairment. Possible scores range from 0 (no symptoms at all) up to 6 (death). Higher scores reflect increased disability. A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 63)	1.66 (± 1.00)	1.97 (± 0.98)		
Change from Baseline at Week 24 (n=19, 54)	-0.05 (± 0.40)	-0.04 (± 0.64)		
Change from Baseline at Week 48 (n=17, 46)	0.00 (± 0.94)	-0.13 (± 0.78)		
Change from Baseline at Week 72 (n=13, 43)	-0.08 (± 1.04)	-0.12 (± 0.63)		
Change from Baseline at Week 96 (n=8, 31)	-0.38 (± 0.74)	-0.42 (± 0.99)		
Change from Baseline at Week 120 (n=3, 16)	-1.00 (± 0.00)	-0.13 (± 0.81)		
Change from Baseline at Week 144 (n=2, 11)	-1.00 (± 1.41)	-0.09 (± 0.54)		
Change from Baseline at Week 168 (n=0, 10)	6666 (± 6666)	0.00 (± 0.67)		
Change from Baseline at Week 192 (n=1, 2)	-1.00 (± 9999)	-0.50 (± 2.12)		
Change from Baseline at Week 216 (n=1, 0)	-1.00 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period
-----------------	---

End point description:

The ZBI is the measurement to assess caregiver burden. The 22 items ask for the strain caregivers perceive. Responses range from 0 (never) to 4 (nearly always). The overall ZBI score ranges from 0 to 88. The higher the total score, the heavier the perceived burden. A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 120

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	8		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=7, 8)	19.43 ( $\pm$ 12.19)	11.32 ( $\pm$ 7.20)		
Change from Baseline at Week 24 (n=6, 4)	0.00 ( $\pm$ 6.20)	1.50 ( $\pm$ 9.68)		
Change from Baseline at Week 48 (n=6, 2)	-2.83 ( $\pm$ 6.11)	-3.00 ( $\pm$ 9.90)		
Change from Baseline at Week 72 (n=3, 1)	-5.00 ( $\pm$ 3.00)	-13.00 ( $\pm$ 9999)		
Change from Baseline at Week 96 (n=2, 0)	-1.00 ( $\pm$ 7.07)	6666 ( $\pm$ 6666)		
Change from Baseline at Week 120 (n=1, 0)	4.00 ( $\pm$ 9999)	6666 ( $\pm$ 6666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period
-----------------	--

End point description:

The EDSS is an ordinal scale with values from 0 points (normal neurological examination) to 10 points (death) increasing in half-point increments once an EDSS of 1.0 has been reached. Higher scores represent increased disability. A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=32, 63)	3.66 (± 1.61)	3.92 (± 1.50)		
Change from Baseline at Week 24 (n=20, 53)	-0.03 (± 0.38)	-0.24 (± 0.71)		
Change from Baseline at Week 48 (n=18, 46)	-0.06 (± 0.42)	-0.32 (± 0.65)		
Change from Baseline at Week 72 (n=12, 42)	0.21 (± 0.58)	-0.29 (± 0.76)		
Change from Baseline at Week 96 (n=8, 29)	-0.50 (± 0.76)	-0.03 (± 0.48)		
Change from Baseline at Week 120 (n=3, 16)	-0.50 (± 0.87)	-0.22 (± 0.91)		
Change from Baseline at Week 144 (n=2, 11)	-1.00 (± 0.71)	0.18 (± 0.68)		
Change from Baseline at Week 168 (n=1, 10)	-0.50 (± 9999)	-0.15 (± 1.13)		
Change from Baseline at Week 192 (n=1, 2)	0.00 (± 9999)	0.25 (± 1.06)		
Change from Baseline at Week 216 (n=1, 0)	-0.50 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period
End point description:	
Visual acuity was measured using Snellen 20-foot wall chart and then converted to logMAR visual acuity scoring. Lower values indicate better visual acuity. Data are reported for right eye (OD) and left eye (OS). A negative change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.	
End point type	Secondary
End point timeframe:	
Baseline up to Week 216	

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline: OD (n=32, 63)	0.560 (± 0.903)	0.449 (± 0.712)		
Baseline: OS (n=32, 63)	0.456 (± 0.811)	0.545 (± 0.836)		
Change from Baseline at Week 24: OD (n=20, 53)	-0.058 (± 0.512)	0.039 (± 0.434)		
Change from Baseline at Week 24: OS (n=20, 53)	0.046 (± 0.242)	-0.001 (± 0.500)		
Change from Baseline at Week 48: OD (n=18, 46)	-0.027 (± 0.097)	0.053 (± 0.434)		
Change from Baseline at Week 48: OS (n=18, 46)	0.050 (± 0.252)	-0.006 (± 0.591)		
Change from Baseline at Week 72: OD (n=12, 42)	-0.050 (± 0.140)	-0.056 (± 0.260)		
Change from Baseline at Week 72: OS (n=12, 42)	-0.083 (± 0.595)	-0.101 (± 0.492)		
Change from Baseline at Week 96: OD (n=8, 29)	-0.045 (± 0.099)	-0.081 (± 0.580)		
Change from Baseline at Week 96: OS (n=8, 29)	-0.260 (± 0.707)	-0.121 (± 0.571)		
Change from Baseline at Week 120: OD (n=3, 16)	-0.027 (± 0.142)	-0.039 (± 0.637)		
Change from Baseline at Week 120: OS (n=3, 15)	0.000 (± 0.000)	-0.229 (± 0.754)		
Change from Baseline at Week 144: OD (n=2, 11)	0.010 (± 0.127)	0.149 (± 0.618)		
Change from Baseline at Week 144: OS (n=2, 11)	0.000 (± 0.000)	-0.280 (± 0.846)		
Change from Baseline at Week 168: OD (n=1, 10)	-0.080 (± 9999)	0.134 (± 0.663)		
Change from Baseline at Week 168: OS (n=1, 10)	-0.100 (± 9999)	-0.320 (± 0.910)		
Change from Baseline at Week 192: OD (n=1, 2)	-0.180 (± 9999)	-0.110 (± 0.156)		
Change from Baseline at Week 192: OS (n=1, 2)	0.080 (± 9999)	-0.050 (± 0.071)		
Change from Baseline at Week 216: OD (n=1, 0)	-0.180 (± 9999)	6666 (± 6666)		
Change from Baseline at Week 216: OS (n=1, 0)	-0.100 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Visual Function (Low-Contrast Sloan Letter Chart [LCSLC]) Scores at 24 Week Intervals During the DB Period

End point title	Change from Baseline in Visual Function (Low-Contrast Sloan Letter Chart [LCSLC]) Scores at 24 Week Intervals During the DB Period
-----------------	--

## End point description:

The LCSLC evaluates the visual function and captures the minimum size at which individuals can perceive letters of a particular contrast level. The change in binocular visual acuity, as assessed by the number of letters read correctly from a distance of 2 meters on 100%, 2.5% and 1.25% contrast level Sloan letter charts, was analyzed. The LCSLC is scored on a scale of 0-60. Higher scores indicate better visual function. A positive change from baseline indicates an improvement. ITT population included all participants randomized to the treatment groups. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	60		
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline: 100% CHART (n=29, 60)	44.3 (± 16.1)	44.4 (± 16.3)		
Baseline: 2.5% CHART (n=29, 60)	24.6 (± 16.2)	22.6 (± 15.6)		
Baseline: 1.25% CHART (n=29, 60)	17.5 (± 15.7)	14.9 (± 14.8)		
Change at Week 24: 100% CHART (n=19, 49)	0.5 (± 7.1)	2.0 (± 5.3)		
Change at Week 24: 2.5% CHART (n=19, 49)	-2.8 (± 9.1)	1.7 (± 7.1)		
Change at Week 24: 1.25% CHART (n=19, 49)	-4.2 (± 11.9)	0.1 (± 7.5)		
Change at Week 48: 100% CHART (n=16, 43)	-3.4 (± 8.7)	1.3 (± 6.1)		
Change at Week 48: 2.5% CHART (n=15, 43)	1.5 (± 6.1)	4.0 (± 9.2)		
Change at Week 48: 1.25% CHART (n=15, 43)	1.7 (± 11.3)	4.1 (± 9.3)		
Change at Week 72: 100% CHART (n=11, 41)	0.3 (± 5.9)	2.8 (± 7.3)		
Change at Week 72: 2.5% CHART (n=11, 41)	-0.6 (± 8.6)	2.6 (± 7.5)		
Change at Week 72: 1.25% CHART (n=11, 41)	-2.4 (± 8.3)	0.4 (± 10.6)		
Change at Week 96: 100% CHART (n=7, 28)	3.3 (± 13.2)	2.1 (± 12.4)		
Change at Week 96: 2.5% CHART (n=7, 28)	2.6 (± 20.1)	2.3 (± 10.8)		
Change at Week 96: 1.25% CHART (n=7, 28)	-3.4 (± 11.3)	-0.5 (± 11.3)		
Change at Week 120: 100% CHART (n=3, 14)	-1.0 (± 1.0)	1.5 (± 10.6)		
Change at Week 120: 2.5% CHART (n=3, 14)	3.7 (± 4.6)	2.1 (± 7.3)		
Change at Week 120: 1.25% CHART (n=3, 14)	-2.0 (± 5.0)	1.6 (± 9.1)		
Change at Week 144: 100% CHART (n=2, 10)	-3.5 (± 2.1)	0.4 (± 7.7)		
Change at Week 144: 2.5% CHART (n=2, 10)	17.5 (± 17.7)	1.6 (± 12.0)		

Change at Week 144: 1.25% CHART (n=2, 10)	-7.0 (± 7.1)	1.4 (± 12.2)		
Change at Week 168: 100% CHART (n=0, 10)	6666 (± 6666)	2.1 (± 6.7)		
Change at Week 168: 2.5% CHART (n=0, 10)	6666 (± 6666)	6.2 (± 8.2)		
Change at Week 168: 1.25% CHART (n=0, 10)	6666 (± 6666)	0.3 (± 12.2)		
Change at Week 192: 100% CHART (n=1, 2)	1.0 (± 9999)	-2.5 (± 3.5)		
Change at Week 192: 2.5% CHART (n=1, 2)	-1.0 (± 9999)	-1.0 (± 4.2)		
Change at Week 192: 1.25% CHART (n=1, 2)	-8.0 (± 9999)	-4.0 (± 7.1)		
Change at Week 216: 100% CHART (n=1, 0)	0.0 (± 9999)	6666 (± 6666)		
Change at Week 216: 2.5% CHART (n=1, 0)	-1.0 (± 9999)	6666 (± 6666)		
Change at Week 216: 1.25% CHART (n=1, 0)	-8.0 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with at Least One Adverse Event in the Double-Blind Period

End point title	Number of Participants with at Least One Adverse Event in the Double-Blind Period
-----------------	---

End point description:

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. The Safety Analysis Population (SAF) included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: participants	24	58		

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Number of Participants with at Least One Serious Adverse Event in the Double-Blind Period**

---

End point title	Number of Participants with at Least One Serious Adverse Event in the Double-Blind Period
-----------------	---

End point description:

A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is medically significant or requires intervention to prevent one or other of the outcomes listed above. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 216

---

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: participants	5	12		

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Number of Participants with Non-Serious Adverse Events of Special Interest in the Double-Blind Period**

---

End point title	Number of Participants with Non-Serious Adverse Events of Special Interest in the Double-Blind Period
-----------------	---

End point description:

Non-serious adverse events of special interest for this study included: 1) cases of an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice, 2) suspected transmission of an infectious agent by the study treatment. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 216

---

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: participants	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Selected Adverse Events in the Double-Blind Period

End point title	Number of Participants with Selected Adverse Events in the Double-Blind Period
-----------------	--

End point description:

Selected adverse events for this study included: 1) all infections, 2) serious infections, 3) potential opportunistic infections, 4) injection-related reactions (IRRs; an AE which occurred within 24 hours after study treatment injection except where the event was not considered an allergic reaction), 5) psychiatric disorders and 6) anaphylaxis (an acute allergic/hypersensitivity reaction). The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: participants				
All Infections	14	34		
Serious Infections	3	6		
Potential Opportunistic Infections	5	3		
Injection-related Reactions	5	8		
Psychiatric Disorders	4	13		
Anaphylaxis	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the Double-Blind Period

End point title	Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the Double-Blind Period
-----------------	---



**End point description:**

The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool to evaluate suicidal ideation and behavior. Categories have binary responses (yes/no) and include: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation or behavior is indicated by a "yes" answer to any of the listed categories. A score of 0 is assigned if no suicide risk is present. A score of 1 or higher indicates suicidal ideation or behavior. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baseline and Post-Baseline (up to Week 216)

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: participants				
Baseline	0	9		
Post-Baseline	1	3		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Serum Satralizumab Concentration During the DB Period**

End point title	Serum Satralizumab Concentration During the DB Period <sup>[3]</sup>
-----------------	--

**End point description:**

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. Participants from SAF who received satralizumab were evaluated for this endpoint. 9999=SD was not calculable for 1 participant.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baseline, Weeks 2, 4, 5, 6, 8, and every 4 weeks thereafter up to Week 204

**Notes:**

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint only reports data for the arm that received satralizumab.

End point values	Satralizumab, then Satralizumab			
Subject group type	Reporting group			
Number of subjects analysed	62			
Units: ng/mL				
arithmetic mean (standard deviation)				
Baseline (n= 62)	145.13 (± 274.87)			

Week 2 (n= 61)	8099.70 ( $\pm$ 4541.66)			
Week 4 (n= 56)	14602.50 ( $\pm$ 8931.85)			
Week 5 (n= 44)	22564.32 ( $\pm$ 12306.09)			
Week 6 (n= 42)	20991.43 ( $\pm$ 12515.82)			
Week 8 (n= 60)	14864.35 ( $\pm$ 9955.41)			
Week 12 (n= 55)	14760.33 ( $\pm$ 10695.11)			
Week 16 (n= 53)	14613.11 ( $\pm$ 11276.95)			
Week 20 (n= 55)	14136.62 ( $\pm$ 12489.83)			
Week 24 (n= 55)	15634.18 ( $\pm$ 13310.22)			
Week 28 (n= 53)	15538.38 ( $\pm$ 13406.73)			
Week 32 (n= 52)	15111.94 ( $\pm$ 13827.06)			
Week 36 (n= 50)	16068.58 ( $\pm$ 14643.61)			
Week 40 (n= 46)	15428.04 ( $\pm$ 16059.35)			
Week 44 (n= 46)	16110.00 ( $\pm$ 15363.29)			
Week 48 (n= 44)	16701.16 ( $\pm$ 16790.77)			
Week 52 (n= 44)	15300.57 ( $\pm$ 14701.05)			
Week 56 (n= 45)	16390.82 ( $\pm$ 16130.69)			
Week 60 (n= 43)	16050.81 ( $\pm$ 14779.35)			
Week 64 (n= 42)	14385.10 ( $\pm$ 14084.24)			
Week 68 (n= 41)	14010.46 ( $\pm$ 13614.03)			
Week 72 (n= 42)	12895.69 ( $\pm$ 13849.12)			
Week 76 (n= 42)	14139.31 ( $\pm$ 14549.71)			
Week 80 (n= 42)	12709.79 ( $\pm$ 14098.26)			
Week 84 (n= 40)	11725.05 ( $\pm$ 13654.04)			
Week 88 (n= 35)	13733.17 ( $\pm$ 13438.07)			
Week 92 (n= 32)	12928.13 ( $\pm$ 13302.53)			
Week 96 (n= 31)	14036.58 ( $\pm$ 12644.16)			
Week 100 (n= 20)	14186.50 ( $\pm$ 12888.23)			
Week 104 (n= 22)	16647.00 ( $\pm$ 15568.61)			
Week 108 (n= 22)	15970.00 ( $\pm$ 13525.53)			
Week 112 (n= 19)	18657.37 ( $\pm$ 17426.82)			

Week 116 (n= 15)	17677.33 (± 16892.59)			
Week 120 (n= 14)	16615.00 (± 16751.13)			
Week 124 (n= 15)	13734.00 (± 12687.75)			
Week 128 (n= 15)	13738.00 (± 16005.33)			
Week 132 (n= 15)	13311.73 (± 15401.04)			
Week 136 (n= 13)	14208.54 (± 15266.48)			
Week 140 (n= 13)	13404.62 (± 12392.48)			
Week 144 (n= 11)	16138.18 (± 13782.26)			
Week 148 (n= 12)	14044.33 (± 12082.37)			
Week 152 (n= 12)	14644.42 (± 13123.67)			
Week 156 (n= 11)	18856.36 (± 20378.31)			
Week 160 (n= 11)	15238.18 (± 11360.62)			
Week 164 (n= 11)	14760.00 (± 11479.99)			
Week 168 (n= 10)	14199.60 (± 9911.22)			
Week 172 (n= 7)	17971.43 (± 16962.78)			
Week 176 (n= 7)	17922.86 (± 12815.57)			
Week 180 (n= 7)	15981.43 (± 9640.78)			
Week 184 (n= 6)	17911.67 (± 15142.19)			
Week 188 (n= 4)	16442.50 (± 13180.44)			
Week 192 (n= 2)	28750.00 (± 22415.28)			
Week 196 (n= 2)	26850.00 (± 20152.54)			
Week 200 (n= 1)	45000.00 (± 9999)			
Week 204 (n= 1)	34500.00 (± 9999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Interleukin-6 (IL-6) Concentration During the DB Period

End point title	Serum Interleukin-6 (IL-6) Concentration During the DB Period
-----------------	---

End point description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	62		
Units: pg/mL				
arithmetic mean (standard deviation)				
Baseline (n=29, 62)	3.66 (± 6.49)	3.49 (± 5.14)		
Week 2 (n=30, 60)	5.90 (± 16.31)	30.14 (± 26.07)		
Week 4 (n=28, 61)	5.41 (± 10.02)	51.53 (± 126.49)		
Week 8 (n=26, 61)	3.30 (± 4.59)	30.88 (± 25.57)		
Week 12 (n=25, 53)	3.40 (± 4.21)	32.02 (± 24.91)		
Week 16 (n=23, 53)	3.72 (± 4.54)	28.59 (± 23.27)		
Week 20 (n=22, 55)	2.99 (± 2.88)	24.06 (± 19.59)		
Week 24 (n=20, 55)	3.68 (± 4.02)	26.27 (± 23.19)		
Week 28 (n=20, 53)	3.88 (± 4.24)	26.89 (± 24.01)		
Week 32 (n=22, 52)	3.43 (± 3.20)	33.29 (± 37.93)		
Week 36 (n=20, 50)	3.78 (± 3.65)	26.03 (± 21.75)		
Week 40 (n=19, 46)	4.82 (± 6.45)	24.16 (± 19.93)		
Week 44 (n=18, 46)	3.47 (± 3.65)	26.16 (± 20.39)		
Week 48 (n=17, 43)	4.58 (± 4.21)	29.61 (± 27.37)		
Week 52 (n=18, 44)	3.52 (± 3.36)	26.94 (± 22.26)		
Week 56 (n=15, 45)	4.13 (± 5.26)	33.15 (± 40.66)		
Week 60 (n=12, 43)	3.28 (± 3.65)	31.34 (± 25.38)		
Week 64 (n=14, 41)	4.08 (± 4.48)	30.60 (± 24.55)		
Week 68 (n=14, 41)	2.75 (± 3.35)	30.56 (± 44.67)		
Week 72 (n=12, 41)	2.95 (± 4.80)	23.16 (± 17.54)		
Week 76 (n=12, 42)	2.44 (± 3.04)	24.08 (± 16.78)		
Week 80 (n=11, 41)	1.57 (± 0.00)	24.86 (± 17.89)		
Week 84 (n=12, 40)	2.27 (± 1.84)	27.61 (± 23.04)		
Week 88 (n=9, 35)	1.57 (± 0.00)	26.51 (± 20.07)		

Week 92 (n=10, 31)	3.38 (± 4.80)	25.48 (± 17.24)		
Week 96 (n=7, 31)	1.57 (± 0.00)	24.57 (± 15.25)		
Week 100 (n=5, 18)	1.57 (± 0.00)	26.31 (± 18.74)		
Week 104 (n=7, 22)	1.57 (± 0.00)	26.30 (± 19.96)		
Week 108 (n=6, 21)	1.57 (± 0.00)	27.64 (± 23.97)		
Week 112 (n=3, 19)	1.57 (± 0.00)	27.39 (± 22.72)		
Week 116 (n=4, 15)	1.57 (± 0.00)	31.73 (± 23.27)		
Week 120 (n=3, 13)	1.57 (± 0.00)	55.92 (± 68.46)		
Week 124 (n=3, 15)	1.57 (± 0.00)	29.46 (± 19.49)		
Week 128 (n=2, 14)	1.57 (± 0.00)	31.20 (± 21.29)		
Week 132 (n=2, 15)	1.57 (± 0.00)	33.84 (± 34.36)		
Week 136 (n=2, 13)	1.57 (± 0.00)	51.83 (± 73.68)		
Week 140 (n=1, 12)	1.57 (± 9999)	41.00 (± 45.44)		
Week 144 (n=2, 11)	1.57 (± 0.00)	28.26 (± 25.64)		
Week 148 (n=2, 12)	1.57 (± 0.00)	28.76 (± 21.52)		
Week 152 (n=1, 12)	1.57 (± 9999)	28.07 (± 23.66)		
Week 156 (n=1, 11)	1.57 (± 9999)	27.25 (± 19.19)		
Week 160 (n=1, 11)	1.57 (± 9999)	29.60 (± 20.30)		
Week 164 (n=1, 11)	1.57 (± 9999)	34.00 (± 24.13)		
Week 168 (n=1, 10)	1.57 (± 9999)	26.29 (± 20.85)		
Week 172 (n=1, 7)	1.57 (± 9999)	23.57 (± 6.59)		
Week 176 (n=1, 7)	1.57 (± 9999)	27.73 (± 11.10)		
Week 180 (n=1, 7)	1.57 (± 9999)	24.09 (± 9.21)		
Week 184 (n=1, 6)	3.63 (± 9999)	17.34 (± 8.47)		
Week 188 (n=1, 4)	5.21 (± 9999)	17.78 (± 7.22)		
Week 192 (n=1, 2)	1.57 (± 9999)	16.55 (± 3.89)		
Week 196 (n=1, 2)	1.57 (± 9999)	14.45 (± 2.76)		
Week 200 (n=1, 1)	1.57 (± 9999)	36.90 (± 9999)		
Week 204 (n=1, 1)	1.57 (± 9999)	12.30 (± 9999)		
Week 208 (n=1, 0)	1.57 (± 9999)	6666 (± 6666)		
Week 212 (n=1, 0)	1.57 (± 9999)	6666 (± 6666)		
Week 216 (n=1, 0)	1.57 (± 9999)	6666 (± 6666)		

## Statistical analyses

**Secondary: Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period**

End point title	Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period
-----------------	---

End point description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	62		
Units: ng/mL				
arithmetic mean (standard deviation)				
Baseline (n=32, 62)	31.88 (± 7.50)	33.18 (± 7.72)		
Week 2 (n=30, 61)	32.72 (± 8.09)	396.49 (± 80.09)		
Week 4 (n=29, 61)	44.79 (± 64.73)	509.21 (± 121.99)		
Week 8 (n=27, 61)	33.23 (± 7.21)	560.63 (± 164.11)		
Week 12 (n=26, 55)	33.02 (± 7.65)	582.36 (± 169.71)		
Week 16 (n=24, 53)	31.60 (± 8.18)	582.22 (± 204.20)		
Week 20 (n=22, 55)	32.99 (± 8.14)	555.64 (± 210.76)		
Week 24 (n=20, 55)	32.47 (± 8.69)	573.01 (± 217.93)		
Week 28 (n=20, 53)	31.83 (± 9.71)	565.29 (± 219.88)		
Week 32 (n=22, 52)	33.33 (± 9.97)	564.13 (± 215.59)		
Week 36 (n=20, 50)	34.03 (± 7.79)	572.31 (± 207.35)		
Week 40 (n=19, 46)	33.64 (± 9.44)	554.90 (± 241.34)		
Week 44 (n=18, 46)	33.97 (± 9.05)	585.62 (± 219.45)		
Week 48 (n=17, 44)	33.72 (± 8.18)	591.06 (± 213.04)		
Week 52 (n=18, 44)	33.47 (± 7.58)	575.56 (± 210.84)		
Week 56 (n=15, 45)	30.34 (± 5.21)	585.40 (± 233.38)		
Week 60 (n=13, 43)	30.58 (± 6.81)	586.40 (± 226.21)		
Week 64 (n=14, 42)	32.27 (± 7.63)	602.72 (± 239.25)		

Week 68 (n=14, 41)	31.19 (± 7.23)	617.80 (± 244.63)		
Week 72 (n=13, 42)	31.12 (± 7.76)	543.95 (± 224.00)		
Week 76 (n=12, 42)	30.56 (± 7.06)	558.67 (± 234.41)		
Week 80 (n=11, 41)	33.36 (± 9.91)	558.73 (± 235.60)		
Week 84 (n=12, 40)	30.95 (± 8.96)	552.37 (± 226.76)		
Week 88 (n=10, 35)	32.05 (± 7.23)	547.93 (± 211.74)		
Week 92 (n=10, 32)	28.93 (± 5.72)	580.64 (± 201.78)		
Week 96 (n=,8 31)	32.88 (± 5.62)	561.64 (± 205.00)		
Week 100 (n=7, 19)	31.84 (± 7.62)	559.18 (± 194.43)		
Week 104 (n=7, 22)	31.70 (± 8.81)	598.05 (± 192.99)		
Week 108 (n=6, 21)	30.55 (± 6.94)	592.06 (± 193.20)		
Week 112 (n=4, 19)	29.93 (± 8.47)	603.31 (± 227.68)		
Week 116 (n=4, 15)	34.30 (± 13.37)	609.37 (± 198.61)		
Week 120 (n=3, 13)	38.20 (± 10.96)	625.15 (± 229.67)		
Week 124 (n=3, 15)	37.87 (± 13.59)	580.07 (± 240.15)		
Week 128 (n=2, 15)	44.50 (± 2.40)	574.54 (± 214.94)		
Week 132 (n=2, 15)	29.80 (± 8.63)	575.40 (± 213.45)		
Week 136 (n=2, 13)	29.45 (± 11.53)	593.92 (± 209.84)		
Week 140 (n=1, 13)	37.20 (± 9999)	627.32 (± 232.08)		
Week 144 (n=2, 11)	31.10 (± 10.18)	693.82 (± 239.70)		
Week 148 (n=2, 12)	28.55 (± 13.08)	690.83 (± 142.94)		
Week 152 (n=1, 12)	33.60 (± 9999)	626.41 (± 229.59)		
Week 156 (n=1, 11)	39.90 (± 9999)	682.82 (± 156.88)		
Week 160 (n=1, 11)	45.00 (± 9999)	694.18 (± 127.92)		
Week 164 (n=1, 11)	43.00 (± 9999)	696.18 (± 106.76)		
Week 168 (n=1, 10)	40.60 (± 9999)	681.00 (± 122.60)		
Week 172 (n=1, 7)	49.70 (± 9999)	672.71 (± 107.83)		
Week 176 (n=1, 7)	45.50 (± 9999)	700.71 (± 90.64)		
Week 180 (n=1, 7)	55.60 (± 9999)	702.00 (± 75.60)		
Week 184 (n=1, 6)	41.60 (± 9999)	678.33 (± 78.20)		
Week 188 (n=1, 4)	40.00 (± 9999)	688.75 (± 143.82)		

Week 192 (n=1, 2)	43.40 (± 9999)	668.00 (± 192.33)		
Week 196 (n=1, 2)	38.00 (± 9999)	630.00 (± 141.42)		
Week 200 (n=1, 1)	35.80 (± 9999)	815.00 (± 9999)		
Week 204 (n=1, 1)	33.70 (± 9999)	783.00 (± 9999)		
Week 208 (n=1, 0)	35.60 (± 9999)	6666 (± 6666)		
Week 212 (n=1, 0)	30.50 (± 9999)	6666 (± 6666)		
Week 216 (n=1, 0)	37.60 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period

End point title	Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period
-----------------	--

End point description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. 9999=SD was not calculable for 1 participant. 6666=0 participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	63		
Units: mg/L				
arithmetic mean (standard deviation)				
Baseline (n=32, 63)	3.08 (± 3.77)	4.95 (± 8.67)		
Week 2 (n=30, 62)	3.51 (± 4.55)	0.93 (± 2.35)		
Week 4 (n=29, 60)	3.45 (± 6.24)	0.82 (± 1.64)		
Week 8 (n=27, 61)	4.56 (± 8.97)	0.83 (± 1.99)		
Week 12 (n=26, 55)	4.23 (± 7.23)	1.23 (± 3.19)		
Week 16 (n=24, 53)	5.30 (± 9.17)	1.56 (± 4.53)		
Week 20 (n=22, 55)	4.07 (± 5.20)	1.78 (± 3.72)		
Week 24 (n=19, 55)	3.53 (± 4.08)	1.72 (± 4.05)		
Week 28 (n=20, 53)	5.85 (± 9.99)	2.35 (± 5.61)		
Week 32 (n=22, 52)	3.97 (± 5.20)	2.06 (± 4.28)		
Week 36 (n=20, 50)	3.77 (± 4.40)	1.56 (± 3.36)		
Week 40 (n=18, 45)	6.77 (± 10.92)	2.55 (± 5.53)		
Week 44 (n=18, 46)	5.44 (± 8.72)	3.31 (± 11.31)		
Week 48 (n=17, 44)	4.70 (± 5.43)	1.79 (± 3.24)		
Week 52 (n=18, 42)	3.82 (± 4.75)	1.90 (± 3.69)		



Week 56 (n=15, 45)	5.33 (± 8.87)	2.32 (± 5.44)		
Week 60 (n=13, 43)	4.54 (± 5.60)	3.20 (± 11.86)		
Week 64 (n=14, 43)	3.76 (± 4.62)	1.92 (± 3.55)		
Week 68 (n=14, 42)	3.30 (± 5.11)	3.65 (± 8.52)		
Week 72 (n=13, 42)	5.07 (± 11.87)	3.33 (± 7.30)		
Week 76 (n=12, 42)	1.98 (± 2.12)	2.79 (± 6.54)		
Week 80 (n=11, 41)	1.10 (± 0.72)	2.83 (± 7.09)		
Week 84 (n=12, 40)	2.31 (± 4.66)	3.81 (± 10.18)		
Week 88 (n=10, 35)	1.94 (± 3.38)	2.64 (± 6.56)		
Week 92 (n=10, 32)	4.49 (± 10.18)	1.94 (± 4.11)		
Week 96 (n=8, 31)	1.76 (± 2.47)	1.64 (± 3.37)		
Week 100 (n=7, 20)	0.90 (± 0.87)	1.87 (± 4.28)		
Week 104 (n=7, 22)	1.13 (± 1.01)	1.93 (± 4.43)		
Week 108 (n=6, 21)	2.20 (± 3.16)	2.56 (± 7.40)		
Week 112 (n=4, 19)	2.25 (± 2.68)	1.53 (± 2.86)		
Week 116 (n=4, 15)	2.28 (± 3.41)	1.19 (± 1.93)		
Week 120 (n=2, 14)	1.55 (± 1.63)	6.05 (± 14.33)		
Week 124 (n=3, 15)	1.50 (± 1.04)	3.24 (± 8.32)		
Week 128 (n=2, 15)	0.65 (± 0.64)	3.09 (± 7.52)		
Week 132 (n=2, 15)	2.55 (± 1.77)	2.66 (± 5.04)		
Week 136 (n=2, 15)	2.70 (± 1.27)	2.85 (± 7.29)		
Week 140 (n=1, 13)	2.50 (± 9999)	4.54 (± 9.57)		
Week 144 (n=2, 11)	2.65 (± 2.19)	0.96 (± 1.75)		
Week 148 (n=2, 12)	4.80 (± 0.99)	0.87 (± 1.44)		
Week 152 (n=1, 12)	1.20 (± 9999)	0.79 (± 0.79)		
Week 156 (n=1, 11)	1.80 (± 9999)	0.71 (± 1.17)		
Week 160 (n=1, 11)	1.20 (± 9999)	0.82 (± 1.36)		
Week 164 (n=1, 11)	1.30 (± 9999)	0.54 (± 0.50)		
Week 168 (n=1, 10)	1.30 (± 9999)	0.37 (± 0.22)		
Week 172 (n=1, 7)	1.30 (± 9999)	0.19 (± 0.09)		
Week 176 (n=1, 7)	1.30 (± 9999)	0.25 (± 0.17)		
Week 180 (n=1, 7)	1.20 (± 9999)	0.27 (± 0.16)		
Week 184 (n=1, 6)	1.10 (± 9999)	0.22 (± 0.11)		
Week 188 (n=1, 4)	2.40 (± 9999)	0.21 (± 0.13)		
Week 192 (n=1, 2)	1.10 (± 9999)	0.33 (± 0.25)		
Week 196 (n=1, 2)	2.00 (± 9999)	0.15 (± 0.00)		
Week 200 (n=1, 1)	1.10 (± 9999)	0.50 (± 9999)		
Week 204 (n=0, 1)	6666 (± 6666)	0.15 (± 9999)		
Week 208 (n=1, 0)	1.00 (± 9999)	6666 (± 6666)		
Week 212 (n=1, 0)	1.60 (± 9999)	6666 (± 6666)		
Week 216 (n=1, 0)	1.10 (± 9999)	6666 (± 6666)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Blood Anti-Aquaporin-4 (AQP4) Antibody Concentration Over Time

End point title	Blood Anti-Aquaporin-4 (AQP4) Antibody Concentration Over Time
-----------------	--

End point description:

Drift in the anti-AQP4 antibody titer cell-based assay over time confounded longitudinal assessment of anti-AQP4 antibody titers and therefore these results cannot be reported

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 24, 48, and every 24 weeks thereafter of double-blind period; every 24 weeks for first 48 weeks of open-label extension period (up to approximately 6.75 years)

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[4]</sup>	0 <sup>[5]</sup>		
Units: Units/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[4] - Data cannot be reported due to drift in the antibody titer cell-based assay.

[5] - Data cannot be reported due to drift in the antibody titer cell-based assay.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Blood Plasmablasts Over Time

End point title	Percentage of Blood Plasmablasts Over Time
-----------------	--

End point description:

The plasmablast assay lacked the sensitivity required to measure plasmablast levels at baseline in the majority of participants. Since most participants had plasmablast values below lower limit of quantitation (LLOQ) at baseline, longitudinal assessments could not be performed and therefore plasmablast results are not reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 24, 48, and every 24 weeks thereafter of double-blind period (up to approximately 38 months)

End point values	Placebo, then Satralizumab	Satralizumab, then Satralizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>		
Units: percentage of plasmablasts				
arithmetic mean (standard deviation)	()	()		

Notes:

[6] - Data not available due to lack of assay sensitivity.

[7] - Data not available due to lack of assay sensitivity.

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Percentage of Participants with Anti-Drug Antibodies to Satralizumab in the DB Period**

---

End point title	Percentage of Participants with Anti-Drug Antibodies to Satralizumab in the DB Period <sup>[8]</sup>
-----------------	--

End point description:

Reported here is the percentage of participants with at least one positive anti-drug antibody measurement during the DB period. The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo. Participants from SAF who received satralizumab were evaluated for this endpoint. Data was summarized together for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 216

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint only reports data for the arm that received satralizumab.

<b>End point values</b>	Satralizumab, then Satralizumab			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: percentage of participants				
number (not applicable)	71.4			

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to clinical cut-off date, 12 Oct 2018 (up to approximately 217 weeks)

Adverse event reporting additional description:

The SAF included all randomized participants who had received at least 1 dose of satralizumab or placebo.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	Placebo, DB Period
-----------------------	--------------------

Reporting group description:

Participants received matching placebo, subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse.

Reporting group title	Satralizumab, DB Period
-----------------------	-------------------------

Reporting group description:

Participants received satralizumab 120 mg subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse.

Reporting group title	Placebo, then Satralizumab, OLE Period
-----------------------	--

Reporting group description:

Participants received matching placebo, subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD).

Reporting group title	Satralizumab, then Satralizumab, OLE Period
-----------------------	---

Reporting group description:

Participants received satralizumab 120 mg subcutaneous (SC) injection at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter throughout the double-blind (DB) period up to protocol-defined relapse. Following the DB period, all participants received satralizumab 120 mg SC injection at Weeks 0, 2 and 4, and Q4W thereafter up to the clinical cut-off date (CCOD).

Serious adverse events	Placebo, DB Period	Satralizumab, DB Period	Placebo, then Satralizumab, OLE Period
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 32 (15.63%)	12 / 63 (19.05%)	1 / 17 (5.88%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Injury			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			

subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cervical radiculopathy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuromyelitis optica			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Hypothermia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Non-cardiac chest pain			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Visual impairment			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Enterocolitis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Apnoea			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cystitis			

subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary sepsis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Satralizumab, then Satralizumab, OLE Period		
-------------------------------	---	--	--

Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 18 (22.22%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Injury			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural haematoma			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Radius fracture			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bradycardia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cervical radiculopathy			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intracranial aneurysm			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		



Neuromyelitis optica			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Hypothermia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Visual impairment			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Enterocolitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Apnoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cystitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Influenza			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary sepsis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo, DB Period	Satralizumab, DB Period	Placebo, then Satralizumab, OLE Period
Total subjects affected by non-serious adverse events			
subjects affected / exposed	22 / 32 (68.75%)	52 / 63 (82.54%)	16 / 17 (94.12%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 32 (6.25%)	7 / 63 (11.11%)	1 / 17 (5.88%)
occurrences (all)	3	9	1
Influenza like illness			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	3	5	1
Injection site erythema			
subjects affected / exposed	2 / 32 (6.25%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	3	0	2
Oedema peripheral			
subjects affected / exposed	0 / 32 (0.00%)	4 / 63 (6.35%)	1 / 17 (5.88%)
occurrences (all)	0	4	1
Feeling cold			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Injection site bruising			

subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Injection site pain			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	0	3	1
Oedema			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Pain			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	1	2	0
Pyrexia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Swelling			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Smoke sensitivity			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Reproductive system and breast disorders			
Vulvovaginal discomfort			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	1	3	1
Oropharyngeal pain			
subjects affected / exposed	3 / 32 (9.38%)	3 / 63 (4.76%)	0 / 17 (0.00%)
occurrences (all)	3	3	0
Hiccups			

subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Pharyngeal erythema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	1 / 32 (3.13%)	3 / 63 (4.76%)	0 / 17 (0.00%)
occurrences (all)	1	4	0
Rhinitis allergic			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Rhinorrhoea			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 32 (6.25%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	2	2	1
Depression			
subjects affected / exposed	1 / 32 (3.13%)	6 / 63 (9.52%)	0 / 17 (0.00%)
occurrences (all)	1	8	0
Insomnia			
subjects affected / exposed	1 / 32 (3.13%)	5 / 63 (7.94%)	1 / 17 (5.88%)
occurrences (all)	1	5	1
Depressed mood			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 32 (0.00%)	4 / 63 (6.35%)	0 / 17 (0.00%)
occurrences (all)	0	4	0
Blood cholesterol increased			

subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	2 / 17 (11.76%)
occurrences (all)	0	1	2
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 32 (3.13%)	4 / 63 (6.35%)	1 / 17 (5.88%)
occurrences (all)	1	5	1
Lymphocyte count decreased			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	2 / 17 (11.76%)
occurrences (all)	1	4	2
Neutrophil count decreased			
subjects affected / exposed	2 / 32 (6.25%)	1 / 63 (1.59%)	2 / 17 (11.76%)
occurrences (all)	2	1	3
White blood cell count decreased			
subjects affected / exposed	0 / 32 (0.00%)	5 / 63 (7.94%)	1 / 17 (5.88%)
occurrences (all)	0	9	1
Blood fibrinogen decreased			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Blood glucose increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Blood potassium decreased			
subjects affected / exposed	1 / 32 (3.13%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	1	1	1
Blood potassium increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	2
Blood pressure increased			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Blood pressure systolic increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Blood urine present			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0

Capillary nail refill test abnormal subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Coagulation test abnormal subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Complement factor decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Glucose urine present subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Haematocrit increased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Hepatic enzyme increased subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 2	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
International normalised ratio increased subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Low density lipoprotein increased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	1 / 17 (5.88%) 1
Monocyte percentage increased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	1 / 17 (5.88%) 2
Protein urine present			

subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 32 (3.13%)	3 / 63 (4.76%)	2 / 17 (11.76%)
occurrences (all)	1	3	2
Excoriation			
subjects affected / exposed	2 / 32 (6.25%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	2	1	1
Fall			
subjects affected / exposed	2 / 32 (6.25%)	4 / 63 (6.35%)	0 / 17 (0.00%)
occurrences (all)	2	4	0
Arthropod bite			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	1	2	1
Arthropod sting			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Foot fracture			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Joint injury			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Meniscus injury			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Post procedural diarrhoea			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Post procedural stroke			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Post-traumatic neck syndrome			



subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Thermal burn subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	2 / 63 (3.17%) 2	0 / 17 (0.00%) 0
Wound subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 63 (3.17%) 2	1 / 17 (5.88%) 1
Cardiac disorders Coronary artery disease subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Bradycardia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 63 (3.17%) 2	0 / 17 (0.00%) 0
Nervous system disorders Balance disorder subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	2 / 63 (3.17%) 2	0 / 17 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3	3 / 63 (4.76%) 3	2 / 17 (11.76%) 5
Headache subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 5	10 / 63 (15.87%) 13	2 / 17 (11.76%) 2
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	5 / 63 (7.94%) 6	2 / 17 (11.76%) 2
Migraine subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	4 / 63 (6.35%) 4	0 / 17 (0.00%) 0
Anosmia			

subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Subdural effusion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
VIIth nerve paralysis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	1 / 32 (3.13%)	4 / 63 (6.35%)	1 / 17 (5.88%)
occurrences (all)	9	5	1
Lymphadenopathy			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Lymphopenia			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Ear and labyrinth disorders			
Deafness unilateral			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Ear canal erythema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	1 / 32 (3.13%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Ear pruritis			

subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	3 / 63 (4.76%) 5	0 / 17 (0.00%) 0
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Abnormal sensation in eye subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Blepharitis subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Eye pruritus subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 63 (3.17%) 2	0 / 17 (0.00%) 0
Eye pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 63 (3.17%) 4	0 / 17 (0.00%) 0
Ocular hypertension subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Photopsia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Abdominal pain upper			

subjects affected / exposed	1 / 32 (3.13%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	1	1	1
Constipation			
subjects affected / exposed	2 / 32 (6.25%)	3 / 63 (4.76%)	3 / 17 (17.65%)
occurrences (all)	2	3	3
Diarrhoea			
subjects affected / exposed	0 / 32 (0.00%)	5 / 63 (7.94%)	0 / 17 (0.00%)
occurrences (all)	0	19	0
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 32 (6.25%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	2	1	1
Gingival pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	2 / 32 (6.25%)	11 / 63 (17.46%)	3 / 17 (17.65%)
occurrences (all)	6	15	7
Abdominal tenderness			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Aphthous stomatitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Coeliac disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Enteritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Flatulence			
subjects affected / exposed	1 / 32 (3.13%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Food poisoning			
subjects affected / exposed	1 / 32 (3.13%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	1	1	2
Haematochezia			

subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Haemorrhoids			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Vomiting			
subjects affected / exposed	1 / 32 (3.13%)	3 / 63 (4.76%)	0 / 17 (0.00%)
occurrences (all)	1	3	0
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 32 (0.00%)	7 / 63 (11.11%)	1 / 17 (5.88%)
occurrences (all)	0	9	2
Rash			
subjects affected / exposed	1 / 32 (3.13%)	9 / 63 (14.29%)	2 / 17 (11.76%)
occurrences (all)	2	15	2
Alopecia areata			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Dermatitis			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	0	3	1
Dermatitis contact			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Erythema			

subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Eczema			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Ingrown hair			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Macule			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Papule			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	3
Vitiligo			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	2 / 17 (11.76%)
occurrences (all)	1	2	2
Dysuria			
subjects affected / exposed	2 / 32 (6.25%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	2	1	1
Glycosuria			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Hydronephrosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 32 (3.13%)	10 / 63 (15.87%)	1 / 17 (5.88%)
occurrences (all)	1	10	1
Back pain			
subjects affected / exposed	3 / 32 (9.38%)	4 / 63 (6.35%)	2 / 17 (11.76%)
occurrences (all)	3	5	2
Muscle spasms			
subjects affected / exposed	0 / 32 (0.00%)	3 / 63 (4.76%)	0 / 17 (0.00%)
occurrences (all)	0	3	0
Musculoskeletal pain			
subjects affected / exposed	2 / 32 (6.25%)	4 / 63 (6.35%)	0 / 17 (0.00%)
occurrences (all)	2	4	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 32 (0.00%)	4 / 63 (6.35%)	0 / 17 (0.00%)
occurrences (all)	0	4	0
Myalgia			
subjects affected / exposed	0 / 32 (0.00%)	4 / 63 (6.35%)	1 / 17 (5.88%)
occurrences (all)	0	5	1
Pain in extremity			
subjects affected / exposed	3 / 32 (9.38%)	9 / 63 (14.29%)	1 / 17 (5.88%)
occurrences (all)	3	12	1
Flank pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			
subjects affected / exposed	0 / 32 (0.00%)	3 / 63 (4.76%)	0 / 17 (0.00%)
occurrences (all)	0	3	0
Neck pain			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	1	2	0
Pain in jaw			

subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Spinal pain			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	0	2	2
Tendonitis			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Tenosynovitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Infections and infestations			
Bronchitis			
subjects affected / exposed	2 / 32 (6.25%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	2	2	0
Cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	4 / 63 (6.35%)	0 / 17 (0.00%)
occurrences (all)	0	4	0
Gastroenteritis			
subjects affected / exposed	0 / 32 (0.00%)	3 / 63 (4.76%)	0 / 17 (0.00%)
occurrences (all)	0	3	0
Influenza			
subjects affected / exposed	2 / 32 (6.25%)	3 / 63 (4.76%)	1 / 17 (5.88%)
occurrences (all)	3	3	1
Nasopharyngitis			
subjects affected / exposed	1 / 32 (3.13%)	9 / 63 (14.29%)	2 / 17 (11.76%)
occurrences (all)	1	11	2
Oral candidiasis			
subjects affected / exposed	2 / 32 (6.25%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	3	0	2
Tonsillitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	2 / 17 (11.76%)
occurrences (all)	1	0	2



Tooth abscess			
subjects affected / exposed	2 / 32 (6.25%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	2	0	1
Upper respiratory tract infection			
subjects affected / exposed	6 / 32 (18.75%)	10 / 63 (15.87%)	4 / 17 (23.53%)
occurrences (all)	14	20	11
Urinary tract infection			
subjects affected / exposed	8 / 32 (25.00%)	11 / 63 (17.46%)	3 / 17 (17.65%)
occurrences (all)	22	35	10
Conjunctivitis infective			
subjects affected / exposed	1 / 32 (3.13%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Cystitis			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Ear infection			
subjects affected / exposed	1 / 32 (3.13%)	2 / 63 (3.17%)	1 / 17 (5.88%)
occurrences (all)	1	2	1
Febrile infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 63 (1.59%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Fungal infection			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Oral herpes			
subjects affected / exposed	1 / 32 (3.13%)	1 / 63 (1.59%)	1 / 17 (5.88%)
occurrences (all)	1	1	1
Otitis media			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Pyelonephritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 63 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 32 (0.00%)	2 / 63 (3.17%)	0 / 17 (0.00%)
occurrences (all)	0	3	0

Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	1 / 17 (5.88%) 4
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	1 / 63 (1.59%) 1	1 / 17 (5.88%) 1
Metabolism and nutrition disorders			
Copper deficiency subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Dyslipidaemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 63 (1.59%) 1	0 / 17 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Hyperuricaemia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Hypokalaemia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1
Increased appetite subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	0 / 17 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 63 (0.00%) 0	1 / 17 (5.88%) 1

<b>Non-serious adverse events</b>	Satralizumab, then Satralizumab, OLE Period		
Total subjects affected by non-serious adverse events subjects affected / exposed	18 / 18 (100.00%)		
Vascular disorders			
Hypertension subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		

General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Influenza like illness			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	15		
Injection site erythema			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Feeling cold			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Injection site bruising			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Injection site pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Oedema			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pain			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Pyrexia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Swelling			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Immune system disorders			

Seasonal allergy subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Smoke sensitivity subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Reproductive system and breast disorders Vulvovaginal discomfort subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 3		
Hiccups subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Nasal congestion subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2		
Pharyngeal erythema subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Respiratory tract congestion subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Rhinitis allergic subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Psychiatric disorders			

Anxiety			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Depression			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	4		
Depressed mood			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood cholesterol increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Neutrophil count decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	6		
Blood fibrinogen decreased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Blood glucose increased			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood potassium decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood potassium increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood pressure increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	3		
Blood pressure systolic increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Blood urine present			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Capillary nail refill test abnormal			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Coagulation test abnormal			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Complement factor decreased			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Glucose urine present			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Haematocrit increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Haemoglobin decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hepatic enzyme increased			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
International normalised ratio increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Low density lipoprotein increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Monocyte percentage increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Platelet count decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Protein urine present			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Excoriation			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Fall			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	5		
Arthropod bite			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Arthropod sting			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Foot fracture			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Joint injury			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Meniscus injury			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Post procedural diarrhoea			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Post procedural stroke			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Post-traumatic neck syndrome			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Thermal burn			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Wound			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Bradycardia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Tachycardia			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Nervous system disorders			
Balance disorder			



subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Headache			
subjects affected / exposed	5 / 18 (27.78%)		
occurrences (all)	8		
Hypoaesthesia			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	4		
Migraine			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Anosmia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	13		
Sinus headache			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Subdural effusion			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
VIIth nerve paralysis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Lymphadenopathy			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

Lymphopenia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Ear and labyrinth disorders Deafness unilateral subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Ear canal erythema subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Ear pain subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 3		
Ear pruritis subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Vertigo subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 3		
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Abnormal sensation in eye subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Blepharitis subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Eye pruritus subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Eye pain subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Ocular hypertension			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Photopsia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Dry eye			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	17		
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Gingival pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	6 / 18 (33.33%)		
occurrences (all)	8		
Abdominal tenderness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Aphthous stomatitis			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		

Coeliac disease			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Enteritis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Food poisoning			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Haematochezia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Haemorrhoids			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Toothache			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	4		
Rash			

subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	7		
Alopecia areata			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dermatitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dermatitis contact			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Eczema			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Ingrown hair			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Macule			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Papule			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Urticaria			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vitiligo			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

Dysuria			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Glycosuria			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Hydronephrosis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Urinary incontinence			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Back pain			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	5		
Muscle spasms			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Musculoskeletal pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Musculoskeletal stiffness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Pain in extremity			
subjects affected / exposed	6 / 18 (33.33%)		
occurrences (all)	8		
Flank pain			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Joint swelling			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Muscular weakness			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pain in jaw			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Rotator cuff syndrome			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Spinal pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tendonitis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Tenosynovitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		

Influenza			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Oral candidiasis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tonsillitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tooth abscess			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	7 / 18 (38.89%)		
occurrences (all)	24		
Urinary tract infection			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Conjunctivitis infective			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cystitis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Ear infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Febrile infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Fungal infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		



Oral herpes			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Otitis media			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pyelonephritis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Copper deficiency			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dyslipidaemia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hypertriglyceridaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Increased appetite			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Iron deficiency			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 February 2014	V2: Study design: The randomization was stratified by prior therapy for prevention of NMO/NMOSD attack (B-cell depleting therapy or immunosuppressants/others) and the most recent attack in the last one year prior to screening (first attack or relapse). Exclusion criteria: History of drug or alcohol abuse within 1 year prior to baseline; History of acute diverticulitis that, in the Investigator's opinion, may lead to increased risk of complications such as lower gastrointestinal perforation. Screening for possible relapse during the study: A Relapse Assessment Form, including the time and content of every report of a possible event was prepared. Patients were instructed to remember accurately the time and content of every symptom of a possible relapse and to contact the study site if they had such symptoms. During the double-blind period, the site contacted the patient weekly by phone calls between the scheduled site visits, to query for any change in symptoms or other signs of a potential relapse. Assessment for suicidality was added to the safety section (Columbia-Suicide Severity Rating Scale [C-SSRS]). The number of patients who are negative for anti-AQP4 antibody at screening were limited to approximately 30% of total study population.
26 May 2014	V3: Change in protocol-defined relapse: new or worsening neurologic symptoms had to meet any of the listed symptoms. Futility analysis was removed from the role of the independent data monitoring committee (IDMC). Hypersensitivity to gadolinium was removed from the exclusion criteria. Additional procedure was added for scripted questions at patient discontinuation to minimize dropout and not to miss potential relapse. Time limit for participants to report relapse event was set. Beginning time point of TFR was modified to start at randomization. Considering the clinical practice in the US, the permitted treatment for relapse was modified. For general safety patients who had a risk of Stevens-Johnson syndrome (SJS) were excluded from the study.
02 September 2014	V4: Protocol-defined relapse criteria were updated to specify the score increase required to qualify as clinically meaningful for the Expanded Disability Status Scale (EDSS) and Functional System Score (FSS) when the baseline score is zero. Instructions for tuberculosis screening and treatment were updated.
05 November 2015	V5: The right to enter the extension period was modified in that protocol-defined relapse had to be adjudicated by the Clinical Endpoint Committee (CEC) in the double-blind Period. The open-label extension period was extended until commercial availability of the drug. Statistical method for primary analysis was changed to a log-rank based permutation test. Clarification was provided to mention that participants who experienced a relapse during the extension period could continue administration of satralizumab at the discretion of the Investigator. Screening procedure for hepatitis C virus (HCV) was modified to mention that if a patient tested positive, but ribonucleic acid (RNA) was undetectable 12 weeks after HCV treatment completion, the patient could be enrolled. Assessments performed at the Withdrawal visit were provided separately for the double-blind period and extension period. Assessments after Week 48 of the extension period were included, because the open-label extension period was extended until commercial availability.
01 March 2016	V6: Recruitment was changed from North America only to include the rest of the world. Total number of participants in the study was increased to 90. The total number of relapse events was changed because the hazard ratio assumption of satralizumab over placebo was modified. The end of the double-blind period was then defined as the date of primary analysis when the total number of relapses reached 44. Procedure for triplicate ECG was clarified for participants who consented to additional pharmacokinetic (PK) sampling.

13 July 2017	V7: Satralizumab prefilled syringe (PFS) with needle safety device (NSD) was implemented in the study. The number of participants to collect blood sample for plasmablast was expanded to all participants. Clarification was included that Zarit Burden Interview (ZBI) was optional and would be performed in selected countries for caregivers who signed informed consent to caregiver burden assessment.
14 June 2018	V8: To prevent prolonged exposure to an unknown risk-benefit balance drug, the definition of the end of the double-blind period was changed to include a maximal duration completion of 1.5 years after the date of the last participant randomized, if the target number of protocol-defined relapses (PDRs) adjudicated by Clinical Endpoint Committee (CEC) had not been reached. The analysis method for primary endpoint was changed to a stratified two-sided log-rank test using strata of prior therapy for prevention of NMO/NMOSD attack (B-cell depleting therapy or immunosuppressants/others) and the most recent attack in the last one year prior to screening (first attack or relapse). Statistical methods were clarified for VAS in pain score and FACIT fatigue scale score to be ANCOVA with hot-deck imputation. It was clarified that non-linear mixed-effects modeling would be used to analyze the sparse sampling dose-concentration-time data of satralizumab.

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported